‘Challenging’ Times For Sandoz As COVID Bites
Sales And Core Operating Profit See Double-Digit Declines Despite Biopharma Growth
Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.
